Vitality Biopharma Announces Publication of International PCT Patent Filing for Cannabinoid Pharmaceuticals

Prodrug technology enables delivery of cannabinoids without psychoactivity for treatment of pediatric conditions

ID: 1524423
recent pressrelease next pressrelease

(businesspress24) - LOS ANGELES, CA -- (Marketwired) -- 10/16/17 -- (OTCQB: VBIO) ("Vitality" or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.

The publication of the international patent filing is the first public disclosure of its full content, which includes 79 patent claims and almost 200 individual compounds. Novel cannabinoid prodrugs are described for the most common phytocannabinoids, THC, cannabidiol (CBD), and CBDV, as well as a variety of other phytocannabinoids and endocannabinoids. The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide. Coverage of any underlying patent claims would extend to 2035 in the United States, and may be subject to patent term extensions that would extend this patent protection. The full text may be accessed online: "".

In addition, the Company has filed for intellectual property coverage for methods to treat dysbiosis, gastrointestinal infections, and other digestive disorders using cannabinoids. The Company''s prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract and avoids psychoactivity, making them well suited for treatment of pediatric conditions.

"The publication of our international PCT patent filing gives shareholders a way to appreciate the depth and rigor of our work on the development of cannabosides," said Robert Brooke, CEO of Vitality Biopharma. "Intellectual property is at the core of nearly every successful biotechnology or drug development company, so we plan to prosecute these claims and to maximize our coverage both in the U.S. and abroad."


Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: . Follow us on , and .

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


More information:

Keywords (optional):

stvf, vitality-biopharma, cannabinoids, neurological, inflammatory, disorders, multiple-sclerosis,

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: Marketwired
print pressrelease  send to a friend  

Date: 10/16/2017 - 05:00
Language: English
News-ID 1524423
Character count: 3900
Firma: Vitality Biopharma, Inc.
Ansprechpartner: Feedback to about Pressrelease-id:


Number of hits: 231


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 70

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.